Impact on histo-pathological reporting with different specimen collection protocols for TRUS biopsy of the prostate. F Harris, C Fragkopoulou, V Dabbagh,

Slides:

Advertisements

Similar presentations

Updated Abstract T2:ERG Correlation with PCa Aggressiveness Conclusions T2:ERG Assay Clinical Performance The T2:ERG assay described has not been approved.

Advertisements

Impact of cytokeratin-positive cells in bone marrow on survival in patients with non-metastatic prostate cancer treated by radiotherapy PURPOSE To evaluate.

Introduction The incidence of prostate cancer in Asians is lower compared to the Westerners in men with PSA

Diffusion-Weighted Imaging in Magnetic Resonance Imaging for prostate gland in Malaysian males with high prostate specific antigen in the diagnosis of.

Geography coursework: Evaluation

Between-Method Differences in Prostate Specific Antigen Assays Affect Prostate Cancer Risk Prediction by Nomograms C. Stephan, K. Siemβen, H. Cammann,

Prostate Smart Biopsy solutions UC Care Ltd. Proprietary

AUDIT OF COMPLIANCE WITH NHSCSP GUIDELINES REQUIRING MDT REVIEW OF ALL CERVICAL CANCER PATIENTS Dr. M Bhattacharjee Dr. A Mutton Dr. S Nagarajan.

THE CLINICO-PATHOLOGIC PATTERNS OF PROSTATIC DISEASES AND PROSTATE CANCER IN SAUDI PATIENTS Hisham A. M. Mosli, FRCSC, FACS Taha A. Abdel-Meguid, MD Jaudah.

Evaluating Diagnostic Accuracy of Prostate Cancer Using Bayesian Analysis Part of an Undergraduate Research course Chantal D. Larose.

Prostate Cancer Detection in Men with an Initial Diagnosis of Atypical small Acinar Proliferations Dr Charles Chabert The Wollongong Hospital.

A re-audit of Prostate biopsies from January to December 2010 and Dr. M S Siddiqui Consultant Histopathologist University Hospital of North Tees.

Prostate Cancer Genetics and Diagnosis

What is the role of free PSA? Total PSA Range 2.5 to 4.0 ng/ml Age Range (Years) %Free PSA=60 (yrs)All Ages

High-grade Prostatic Intraepithelial Neoplasia on Needle Biopsy Risk of Cancer on Repeat Biopsy Related to Number of Involved Cores and Morphologic Pattern.

USE OF P63 IN ASSESSING MIMICS OF PROSTATIC ADENOCARCINOMA DR. A. T. ATANDA, BAYERO UNIVERSITY/AMINU KANO TEACHING HOSP. KANO.

Prostate Cancer One of the commonest causes of death in the Western World USA 2005 – 232,090 new cases – 30,350 deaths Lifetime risk of disease 16.6% Lifetime.

Role of MRI and MRSI in The Management of Prostate Cancer Karim Touijer, MD.

Mr Jonathan Lewin MBBS, MRCS, MD, FRCS(Urol), FRACS Consultant Uro-Oncological Surgeon.

Prostate Needle Biopsy: The Pitfalls and the Role of the Pathologist – Patient Track Prostate Cancer Symposium “Intriguing Cases / Emerging Strategies.

David Anderson, Bruce Golden, Ed Wasil, Howard Zhang 1 INFORMS Annual Meeting October, 2013.

RISK OF NON SIGNIFICANT PROSTATE CANCER IN PROSTATE CANCER PATIENTS DIAGNOSED BY AN EXTENDED PROSTATE NEEDLE BIOPSY PROCEDURE AND TREATED BY RADICAL PROSTATECTOMY.

Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,

Objectives Abstract Background Materials & Methods References 1.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of.

Dan Spratt, MD Department of Radiation Oncology Neuroendocrine Prostate Cancer: FDG-PET and Targeted Molecular Imaging.

Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.

How do we know whether a marker or model is any good? A discussion of some simple decision analytic methods Carrie Bennette (on behalf of Andrew Vickers)

Biostatistics Case Studies Peter D. Christenson Biostatistician Session 2: Diagnostic Classification.

MRI-Ultrasound Fusion-Guided Biopsy of the Prostate: Results of Initial Experience in a Radiation Oncology Department Department of Radiation Oncology.

Chemotherapy Audit  Audit of patients who died within three months of their last dose of chemotherapy at Airedale General Hospital  The records of 50.

Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain.

The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Fifth Annual African-American Prostate Cancer Disparity Summit September 24, 2009 Christine.

PCa Screening New Areas of Research Francesco Montorsi Milan.

Ten Year Outcomes In Men Under 60 Treated With Iodine-125 Permanent Brachytherapy As Monotherapy GU - Prostate Cancer: Novel Imaging (MRI,PET) & Brachytherapy.

Pathology Reports Nicole Draper, MD.

TEMPLATE DESIGN © ONCOLOGICAL REFERRAL PATTERNS OF GYNAECOLOGICAL CANCER PATIENTS OVER 2010 – 2011 THE NEED FOR GYNAECOLOGIC.

The short term effects of an AKT inhibitor (AZD5363) on biomarkers of the AKT pathway and anti-tumour activity in a breast cancer paired biopsy study (STAKT.

بسم الله الرحمن الرحيم. The role of three dimensional transrectal ultrasonography (3-D TRUS) and power Doppler sonography in prostatic lesions evaluation.

PURPOSE PATIENTS & METHODS RESULTS CONCLUSION DISCUSSION Department of Pathology, King Hussein Cancer Center, Amman, Jordan The general aim of this study.

Ki-67 index cutoff value of 1% is a valuable prognostic biomarker for pulmonary carcinoids based on this large cohort. Our data also provide strong evidence.

Table 1. Characteristics of patients and the results of the log-rank test of prognostic factors Median (range) No. of patients No. of CRPC Median progression.

The Royal Marsden Solitary fibrous tumours The outcomes of 106 patients illustrating the unpredictable biological behaviour N Alexander, K Thway, JM Thomas,

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Comparison of MR/Ultrasound Fusion–Guided Biopsy With.

Prostate cancer update Suresh GANTA Consultant urological surgeon Manor Hospital.

PSA screening Cost Conscious Project Kristopher Huston January 2016.

Assessing Quality of Pathology Reporting: The Case of Tongue Cancer Lihua Liu 1, PhD Wesley Y. Naritoku 2, MD, PhD Juanjuan Zhang 1, MS Lenard Berglund.

Methods Three questionnaires were designed with reference to national guidelines and the PCRMP’s recommendations. These questionnaires were sent to PCTs,

Robotic-assisted Laparoscopic Prostatectomy

Network meeting Taunton Rugby club January 20th

CORRELATION OF PHYSICAL EVALUATION AND MRI OF CERVICAL LYMPH NODE WITH HISTOPATHOLOGICAL FINDINGS IN ORAL SQUAMOUS CELL CARCINOMA: AN AMBIDIRECTIONAL STUDY.

Skin Cancer Diagnoses and Treatments.

Figure 1. Mesothelioma mortality in The Netherlands 1997–2002 (source: Netherlands National Institute of Statistics). From: Occupational asbestos exposure:

Comparison of PSA Values of Prostate Cancer Patients Before, During and After Prostate Biopsy Using Gleason Score Mehmet KILINC1, Yunus Emre GOGER1, Hasan.

Discordance of histo-pathological diagnosis of patients with soft tissue sarcoma referred to tertiary care center. Rastogi,S., Aggarwal, A., Soti, K.,

W. Scott Campbell, MBA, PhD University of Nebraska Medical Center

Segmented analysis of prostate cancer pathway from referral to treatment: This work was carried out in partnership between the Transforming.

W. Scott Campbell, MBA, PhD University of Nebraska Medical Center

Urologist’s Impact on Extended Needle Core Prostate Biopsy Histopathologic Variables within a Single Institution Kashika G. Goyal B.S.1, Joshua J. Ebel.

Apollo Gleneagles Hospitals,

Assessing the validity of Prostate Imaging Reporting and Data System version 2 (PI- RADS v2) scoring system in diagnosis of peripheral zone prostate cancer

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

OF THE EUROPEAN ASSOCIATION OF UROLOGY

Practical of Histopathology

European Urology Oncology

Tissue processing Histology:

Study overview. Study overview. A, Schematic illustrating clinical trial design and the nature and number of tissue specimens available for downstream.

Longer testing interval may impact the outcome of a prostate biopsy following the index PSA test due to longer time for a potential tumour to grow from.

PSMA expression in pre- and posttreatment prostate carcinoma serum.

Oregon HPV Summit - June 2019 Nasreen Abdullah, MD, MPH

Presentation transcript:

Impact on histo-pathological reporting with different specimen collection protocols for TRUS biopsy of the prostate. F Harris, C Fragkopoulou, V Dabbagh, G M Nandwani, S K Addla.

Specimen Collection Techniques Protocol 1 – All specimens from one side sent in a single pot – The technician in pathology lab individually separates them and fixes them on sponges Protocol 2 – Specimen fixed into individual cassettes and sent to pathology lab

Aim & Methods To assess the histo-pathological concordance of number of cores with – Protocol 1 – Protocol 2 Parameters assessed – Cancer diagnosis – Core length – Concordance in number of cores sent and reported

Results Protocol 1 – Feb 2010 – May 2010 – Patients61 – Specimen pots138 Protocol 2 – Apr 2011 – Aug 2011 – Patients74 – Specimen pots163

Results Mean PSA = Mean age = 65 years

Results Protocol 1Protocol 2 Total No. of patients6174 Ca Positive26 (42.6%)37 (50.0%) Core length (mm)Protocol 1 Protocol 2 Range Mean Median 15

Results – Number of cores sent & reported Protocol 1 Protocol 2 Total Number of Patients Discrepancy 42 (68.8%) 23 (31.1%) ( P = 0.01) Concordance 19 (31.2%) 51 (68.9) Total Number of Specimens Discrepancy 60 (43.5%) 31 (19%) ( P = 0.001) Concordance 78 (56.5%) 132 (81%)

Biopsy number-concordance DiscrepancyProtocol 1 Protocol 2 Range1-4 Mean Median1 1 DiscrepancyProtocol 1Protocol 2 Negative4019 Positive2012

Conclusion Overall 50% of patients diagnosed with prostate cancer in Protocol 2 compared to Protocol 1 (42.6%) Improvement in concordance in Protocol 2 from 56.5% to 81.0% Protocol 2 now standard